Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment

Introduction: Breast cancer (BC) is a heterogeneous disease involving a network of numerous extracellular signal transduction pathways. The phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (Akt)/mechanistic target of rapamycin (mTOR) pathway is crucial for understanding the BC development. P...

Full description

Saved in:
Bibliographic Details
Main Authors: Magdalene Eno Effiong, Mercy Bella-Omunagbe, Israel Sunmola Afolabi, Shalom Nwodo Chinedu
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Bioinformatics and Biology Insights
Online Access:https://doi.org/10.1177/11779322251316864
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832542339027959808
author Magdalene Eno Effiong
Mercy Bella-Omunagbe
Israel Sunmola Afolabi
Shalom Nwodo Chinedu
author_facet Magdalene Eno Effiong
Mercy Bella-Omunagbe
Israel Sunmola Afolabi
Shalom Nwodo Chinedu
author_sort Magdalene Eno Effiong
collection DOAJ
description Introduction: Breast cancer (BC) is a heterogeneous disease involving a network of numerous extracellular signal transduction pathways. The phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (Akt)/mechanistic target of rapamycin (mTOR) pathway is crucial for understanding the BC development. Phosphoinositide 3-kinase, phosphatase and tensin homolog (PTEN), mTOR, Akt, 3-phosphoinositide-dependent kinase 1 (PDK1), FoxO1, glycogen synthase kinase 3 (GSK-3), mouse double minute 2 (MDM2), H-Ras, and proapoptotic B-cell lymphoma 2 (BCL-2) family protein (BAD) proteins are key drivers of this pathway and potential therapeutic targets. Pleurotus ostreatus is an edible mushroom that is rich in flavonoids and phenols that can serve as potential inhibitors of proteins in the PI3K/Akt/mTOR pathway. Aim: This study evaluated the anticancer properties of P ostreatus through a structure-based virtual screening of 22 biologically active compounds present in the mushroom. Method: Model optimization was carried out on PI3K, PTEN, mTOR, Akt, PDK1, FoxO1, GSK-3, MDM2, H-Ras, and BAD proteins in the PI3K/Akt/mTOR pathway and molecular docking of compounds/control inhibitors in the binding pocket were simulated AutoDock Vina in PyRx. The drug likeness, pharmacokinetic, and pharmacodynamic features of prospective docking leads were all anticipated. Result: Several potent inhibitors of the selected key driver proteins in PI3K/Akt/mTOR pathway were identified from P ostreatus . Ellagic acid with binding affinities of −8.0, −8.0, −8.1, −8.2, −6.2, and −7.1 kcal/mol on PI3K, Akt, PDK1, GSK-3, MDM2, and BAD, respectively, had better binding affinity compared with their reference drugs. Likewise, apigenin (−7.8 kcal/mol), chrysin (−7.8 kcal/mol), quercetin (−6.4 kcal/mol), and chlorogenic acid (−6.2 kcal/mol) had better binding affinities to PTEN, mTOR, FoxO1, and H-Ras proteins, respectively. Conclusion: Ellagic acid, apigenin, luteolin, quercetin, chlorogenic acid, chrysin, and naringenin phytochemicals are seen as the better lead molecules due to their ability to strongly bind to the proteins under study in this pathway. Analogs of these compounds can also be designed as potential drugs.
format Article
id doaj-art-d90245bac9c44310a915df8b0833c5d0
institution Kabale University
issn 1177-9322
language English
publishDate 2025-02-01
publisher SAGE Publishing
record_format Article
series Bioinformatics and Biology Insights
spelling doaj-art-d90245bac9c44310a915df8b0833c5d02025-02-04T07:03:29ZengSAGE PublishingBioinformatics and Biology Insights1177-93222025-02-011910.1177/11779322251316864Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer TreatmentMagdalene Eno Effiong0Mercy Bella-Omunagbe1Israel Sunmola Afolabi2Shalom Nwodo Chinedu3Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota, NigeriaCovenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota, NigeriaCovenant University Public Health and Wellbeing Research Cluster (CUPHWERC), Covenant University, Ota, NigeriaCovenant University Public Health and Wellbeing Research Cluster (CUPHWERC), Covenant University, Ota, NigeriaIntroduction: Breast cancer (BC) is a heterogeneous disease involving a network of numerous extracellular signal transduction pathways. The phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (Akt)/mechanistic target of rapamycin (mTOR) pathway is crucial for understanding the BC development. Phosphoinositide 3-kinase, phosphatase and tensin homolog (PTEN), mTOR, Akt, 3-phosphoinositide-dependent kinase 1 (PDK1), FoxO1, glycogen synthase kinase 3 (GSK-3), mouse double minute 2 (MDM2), H-Ras, and proapoptotic B-cell lymphoma 2 (BCL-2) family protein (BAD) proteins are key drivers of this pathway and potential therapeutic targets. Pleurotus ostreatus is an edible mushroom that is rich in flavonoids and phenols that can serve as potential inhibitors of proteins in the PI3K/Akt/mTOR pathway. Aim: This study evaluated the anticancer properties of P ostreatus through a structure-based virtual screening of 22 biologically active compounds present in the mushroom. Method: Model optimization was carried out on PI3K, PTEN, mTOR, Akt, PDK1, FoxO1, GSK-3, MDM2, H-Ras, and BAD proteins in the PI3K/Akt/mTOR pathway and molecular docking of compounds/control inhibitors in the binding pocket were simulated AutoDock Vina in PyRx. The drug likeness, pharmacokinetic, and pharmacodynamic features of prospective docking leads were all anticipated. Result: Several potent inhibitors of the selected key driver proteins in PI3K/Akt/mTOR pathway were identified from P ostreatus . Ellagic acid with binding affinities of −8.0, −8.0, −8.1, −8.2, −6.2, and −7.1 kcal/mol on PI3K, Akt, PDK1, GSK-3, MDM2, and BAD, respectively, had better binding affinity compared with their reference drugs. Likewise, apigenin (−7.8 kcal/mol), chrysin (−7.8 kcal/mol), quercetin (−6.4 kcal/mol), and chlorogenic acid (−6.2 kcal/mol) had better binding affinities to PTEN, mTOR, FoxO1, and H-Ras proteins, respectively. Conclusion: Ellagic acid, apigenin, luteolin, quercetin, chlorogenic acid, chrysin, and naringenin phytochemicals are seen as the better lead molecules due to their ability to strongly bind to the proteins under study in this pathway. Analogs of these compounds can also be designed as potential drugs.https://doi.org/10.1177/11779322251316864
spellingShingle Magdalene Eno Effiong
Mercy Bella-Omunagbe
Israel Sunmola Afolabi
Shalom Nwodo Chinedu
Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
Bioinformatics and Biology Insights
title Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
title_full Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
title_fullStr Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
title_full_unstemmed Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
title_short Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment
title_sort molecular docking appraisal of phytochemicals as potential inhibitors of pi3k akt pathway for breast cancer treatment
url https://doi.org/10.1177/11779322251316864
work_keys_str_mv AT magdaleneenoeffiong moleculardockingappraisalofphytochemicalsaspotentialinhibitorsofpi3kaktpathwayforbreastcancertreatment
AT mercybellaomunagbe moleculardockingappraisalofphytochemicalsaspotentialinhibitorsofpi3kaktpathwayforbreastcancertreatment
AT israelsunmolaafolabi moleculardockingappraisalofphytochemicalsaspotentialinhibitorsofpi3kaktpathwayforbreastcancertreatment
AT shalomnwodochinedu moleculardockingappraisalofphytochemicalsaspotentialinhibitorsofpi3kaktpathwayforbreastcancertreatment